There are currently 979 clinical trials in San Antonio, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Health Science Center at San Antonio, GSK Investigational Site, Pfizer Investigational Site and Methodist Children's Hospital of South Texas. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT05611931
Recruiting
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v 1.1\]) after completing at least 12 weeks of platinum-based therapy. A total of 220 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2025
Locations: Texas Oncology - San Antonio, San Antonio, Texas
Conditions: Endometrial Cancer
Register for Updates
Determining Which Regions of the Brain Are Active During Flight Simulation at Separate Timepoints During Training
NCT06606925
Recruiting
The overall objective is to identify the cognitive circuits associated with military aviator performance by analyzing what anatomic regions of the brain are functionally "active" (neuronal circuit) while being performing virtual flight simulations, the Precision Instrument Control Task (PICT). The flight simulation test will be conducted at two separate timepoints while the subject is receiving a Functional Magnetic Resonance Imaging (fMRI) scan to evaluate which anatomic and functional brain fu... Read More
Gender:
ALL
Ages:
Between 18 years and 54 years
Trial Updated:
01/13/2025
Locations: Joint Base San Antonio - Randolph & Lackland, San Antonio, Texas
Conditions: Cognitive Performance
Register for Updates
A Clinical Trial to Assess COM503 in Participants with Advanced Solid Malignancies
NCT06759649
Recruiting
The overall goal of this first-in-human (FIH) clinical trial is to learn about the safety and dosing of COM503 when given alone or in combination with zimberelimab in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of COM503 as monotherapy and COM503 in combination with zimberelimab in participants with advanced solid tumors. * To identify the maximum tolerated dose (MTD) / maximum administered dose (MAD) and/or the rec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: NEXT Oncology San Antonio, San Antonio, Texas +1 locations
Conditions: Neoplasm, Cancer, Malignant Tumors
Register for Updates
Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset
NCT05685745
Recruiting
The goal of the Tiny Baby Collaborative Multicenter Inventory of Neonatal-Perinatal Interventions (MINI) minimum dataset is to serve as a registry detailing the outcomes and practices for all deliveries and infants admitted to intensive care at 22-23 weeks' gestation at participating hospitals.
Gender:
ALL
Ages:
Between 0 years and 1 year
Trial Updated:
01/10/2025
Locations: CHRISTUS Children's Hospital, San Antonio, Texas +3 locations
Conditions: Infant, Extremely Premature, Obstetric Labor, Premature, Premature Birth, Intensive Care, Neonatal, Intensive Care Units, Neonatal
Register for Updates
Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SUVN-I6107 In Healthy Participants
NCT06705088
Recruiting
The purpose of this study is 1) to investigate how safe and tolerable SUVN-I6107 is after a single oral dose at increasing dose levels and multiple oral doses at increasing dose levels, 2) to determine the pharmacokinetic (PK) profile after single and multiple ascending oral doses, 3) to investigate the effects of food on SUVN-I6107 pharmacokinetics and 4) to evaluate the pharmacodynamic (PD) effects of single and multiple ascending oral doses of SUVN-I6107 on quantitative electroencephalogram (... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/08/2025
Locations: Clinical Research Site, San Antonio, Texas
Conditions: Healthy
Register for Updates
Multicenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth In/near Infected Bone Cavities
NCT05361941
Recruiting
This is a pivotal, prospective, multi-center, randomized, concurrent control, patient and assessor-blinded study with two arms: a treatment arm (where subjects will be treated with the EP Granules with Tobramycin investigational device in the 1st stage of a staged revision for periprosthetic joint infection (PJIs), and a control arm (where subjects are treated with the standard-of-care revision for infected PJIs).
Gender:
ALL
Ages:
22 years and above
Trial Updated:
01/07/2025
Locations: UT Health San Antonio, San Antonio, Texas
Conditions: Periprosthetic Joint Infections
Register for Updates
A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors
NCT05957536
Recruiting
This first-in-human (FIH) study, multi-center, open-label, dose escalation and dose expansion Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary anti-tumor activity of D3L-001 in subjects with HER2-positive advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: D3 Bio Investigative Site, San Antonio, Texas
Conditions: HER-2 Positive Advanced Solid Tumors
Register for Updates
Blood Flow Restriction for Optimizing Balance in Parkinson's Disease
NCT06508801
Recruiting
This study is being done to understand how reducing blood flow (BRT) during balance-challenging strengthening exercises (instability resistance training, or IRT) can help improve symptoms of Parkinson's disease.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
01/07/2025
Locations: University of Texas Health Science Center at San Antonio, San Antonio, Texas
Conditions: Parkinson's Disease and Parkinsonism
Register for Updates
Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
NCT03655015
Recruiting
Create a living biobank of PDOs from Stage I-III lung cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: UT Health San Antonio, M.D. Anderson Cancer Center, San Antonio, Texas
Conditions: Lung Neoplasm
Register for Updates
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
NCT06090266
Recruiting
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: NEXT Oncology, San Antonio, Texas
Conditions: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Cutaneous Melanoma, Non-small Cell Lung Cancer
Register for Updates
A Study of BI-1206 in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors (KEYNOTE-A04)
NCT04219254
Recruiting
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with Anti-PD-1 or Anti-PD-L1 Antibodies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2025
Locations: NEXT Oncology, San Antonio, Texas
Conditions: Solid Tumor, Adult
Register for Updates
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
NCT05417321
Recruiting
It is a Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects with Advanced Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2025
Locations: Next Oncology, San Antonio, Texas
Conditions: Advanced Solid Tumor, NSCLC
Register for Updates